The remaining 14 cases showed negative cCD3 by IHC and/or flow cytometry and 12 cases demonstrated concordant cCD3 expression status between IHC and flow cytometry. None of the AMKL with RAM-phenotype or aberrant cCD3 expression showed co-expression of other surface T-cell markers, while the majority of the other AMKL cases showed aberrant surface T-cell expression such as CD2, CD7, or CD4. We report that aberrant cCD3 expression can be detected in infantile/pediatric non-DS AMKL in conjunction with RAM-phenotype and/or I CBFA2T3:GLIS2 i fusions. In 2016, Eidenschink Brodersen et al. from the Children's Oncology Group (COG) described a new high-risk subtype of acute myeloid leukemia (AML) with a distinct immunophenotypic signature termed RAM-phenotype [[1]]. [Extracted from the article]